SCHEMBL422472

SCHEMBL422472

COC(=O)c1cc(Cl)ccc1NC(=O)c1ccc(-c2ccc(F)cc2)s1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRSS12 P56730 3/20 0.54
TP53 P04637 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
ESRRG P62508 10/20 0.53
KDM4E B2RXH2 2/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
ALDH1A1 P00352 1/20 0.52
HPGD P15428 1/20 0.52
MEN1 O00255 1/20 0.51
MAPT P10636 1/20 0.51
KMT2A Q03164 1/20 0.51
ESR1 P03372 5/20 0.50
ESR2 Q92731 2/20 0.50
PTPN2 P17706 1/20 0.50
PTPN11 Q06124 1/20 0.50
MAPK11 Q15759 2/20 0.48
MAPK14 Q16539 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL420763 0.88 PRSS12 (0.69) PRSS12TP53SMN1; SMN2ESRRGKDM4E
SCHEMBL7033055 0.78 PPARG (0.47) PRSS12TP53SMN1; SMN2ESRRGKDM4E
SCHEMBL7037291 0.76 PPARG (0.52) TP53SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL20764080 0.76 ESRRG (0.78) SMN1; SMN2ESRRGKDM4ENPC1RAB9A
SCHEMBL6805238 0.75 KDM4E (0.67) SMN1; SMN2ESRRGKDM4ENPC1RAB9A
SCHEMBL23447371 0.75 IKBKB (0.49) TP53SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL1752547 0.75 MAPK11 (0.71) PRSS12TP53SMN1; SMN2MAPK11MAPK14
SCHEMBL7035471 0.74 PPARG (0.49) TP53SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL1015774 0.73 ALDH1A1 (0.43) TP53SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL27677406 0.73 IKBKB (0.63) TP53SMN1; SMN2ESRRGKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 PRSS12 195/4885TP53 3329/4885SMN1; SMN2 2569/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 PRSS12 195/4885TP53 3329/4885SMN1; SMN2 2569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.